open to eligible people ages 18 years and up
The purpose of this study is to assess the safety of the combination of CORT125134, a novel glucocorticoid receptor (GR) antagonist, and nab-paclitaxel in patients with solid tumors and to determine the preliminary efficacy of the combination of CORT125134 and nab-paclitaxel in patients with solid tumors. The structure for the study is a single arm, non-randomized, open-label, multicenter trial with no control group. The study will be conducted at approximately 8 sites with approximately 82 evaluable patients.
San Francisco, California and other locations